ZURICH, Nov 20 (Reuters) - Swiss shares were seen edging higher on Friday, in line with other European markets, after losses in the previous session.
The blue chip SMI index was expected to open 11 points lower at 6,299 points, according to pre-market data from bank Clariden Leu.
The following are some of the main factors expected to affect Swiss stocks on Friday.
ROCHE
Swiss drugmaker Roche's rheumatoid arthritis drug, Actemra, significantly improved symptoms of systemic onset Juvenile Idiopathic Arthritis (sJIA), meeting its primary goal in a late-stage trial, the group said.
For related news, click on
BALOISE
Continued low interest rates could cause some insurers to collapse, the CEO of Baloise warned on Thursday, using Japan in the 1990s as an example.
For related news, click on
ECONOMY
* SNB Chairman Jean-Pierre Roth speaks in Freibourg at 0915 GMT
COMPANY STATEMENTS
* Nestle: The Board of Directors of Nestle S.A. has decided to appoint Jean-Marc Duvoisin to the Executive Board as Deputy Executive Vice President, Human Resources and Centre Administration, with effect on 1 January 2010.
* Quadrant takeover: Aquamit petitions the cancellation of the remaining publicly held Quadrant shares
* Newron raises 7.9 mln Sfr in a private placement to international investors
* Zueblin shareholders approve nominal value reduction
* Carlo Gavazzi challenging market environment
EQUITY RESEARCH
FOR COMPANIES TRADING EX-DIVIDEND, PLEASE CLICK ON:
for all Swiss stocks
for blue chips
for other stocks
Keywords: MARKETS SWISS STOCKS
(Zurich newsroom +41 58 306 7336, fax 41 44 251 0476, zurich.newsroom@news.reuters.com)
COPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
